Moderna has reported top-line data suggesting that its COVID-19 booster vaccine candidate stimulates a strong immune response against the Omicron subvariants BA.4 and BA.5, which have driven an ...

Moderna has started human trials of an Omicron version of its COVID-19 vaccine SpikeVax, just in case a modified version will be needed to boost protection against the new variant later this year.

Stock markets around the world have fallen after the boss of Moderna cast doubts on the effectiveness of vaccines against the new Omicron Covid variant. Stephane Bancel told the Financial Times he ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Moderna Inc. said Thursday a Phase 3 trial of ... which showed that mRNA-1283 had higher neutralizing antibody responses ...

Australia’s Therapeutic Goods Administration (TGA) has recently approved a new COVID booster. The shot was developed by ...

An Omicron-specific booster could be ready by August, the CEO of U.S. biotech firm Moderna told Reuters, but the firm is still gathering clinical data to determine whether that vaccine would offer ...

The Moderna laboratories Tuesday reported that their two bivalent Omicron-targeting new messenger RNA (mRNA) technology booster vaccines (mRNA-1273.214 and mRNA-1273.222) have a superior antibody ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

The Omicron variant has been shaking the stock ... which was enough to erase $15 billion in Moderna’s market cap. “We see MRNA as a better short-term bet on COVID-19 developments.

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

"The only thing I'm pretty sure that we're not going to face this fall is Omicron," he added, "because it would just seem a bad strategy for the virus to stop evolving." Both Pfizer and Moderna ...